PURPOSE: Many patients with prostate cancer have bone metastases that appear osteoblastic on radiography, and yet these patients are at increased risk for fracture. The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases. MATERIALS AND METHODS: Histomorphometry was used to evaluate multisite bone biopsies in 12 patients who died with multiple bone metastases, of whom 7 had received bisphosphonate therapy. RESULTS: Bone histomorphometry revealed a wide spectrum of cancer induced bone changes in different metastatic sites in individual patients, ranging from a pronounced osteodense to a pronounced osteopenic type. Each metastatic lesion was associated with various amounts of resorption. Decreased bone volume was seen in half of all biopsies. Osteodense lesions were largely composed of under mineralized woven bone, which increases the frailty of new bone. Interestingly woven bone was produced by alkaline phosphatase spindle-shaped cells arising from the connective stroma surrounding tumor cells. The bone response generally was similar in bisphosphonate treated patients and those who did not receive bisphosphonate. CONCLUSIONS: Despite the osteoblastic nature of bone metastases in prostate cancer, the osteolytic-osteopenic bone lesions found in each clinically osteoblastic case may explain the frequent fractures observed in these cases. In addition, the finding that woven bone formed directly from the tumor stroma and not from the adjacent bone surface supports further research into the mechanisms of abnormal bone formation in prostate cancer bone metastases.
PURPOSE: Many patients with prostate cancer have bone metastases that appear osteoblastic on radiography, and yet these patients are at increased risk for fracture. The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases. MATERIALS AND METHODS: Histomorphometry was used to evaluate multisite bone biopsies in 12 patients who died with multiple bone metastases, of whom 7 had received bisphosphonate therapy. RESULTS: Bone histomorphometry revealed a wide spectrum of cancer induced bone changes in different metastatic sites in individual patients, ranging from a pronounced osteodense to a pronounced osteopenic type. Each metastatic lesion was associated with various amounts of resorption. Decreased bone volume was seen in half of all biopsies. Osteodense lesions were largely composed of under mineralized woven bone, which increases the frailty of new bone. Interestingly woven bone was produced by alkaline phosphatase spindle-shaped cells arising from the connective stroma surrounding tumor cells. The bone response generally was similar in bisphosphonate treated patients and those who did not receive bisphosphonate. CONCLUSIONS: Despite the osteoblastic nature of bone metastases in prostate cancer, the osteolytic-osteopenic bone lesions found in each clinically osteoblastic case may explain the frequent fractures observed in these cases. In addition, the finding that woven bone formed directly from the tumor stroma and not from the adjacent bone surface supports further research into the mechanisms of abnormal bone formation in prostate cancer bone metastases.
Authors: A Berruti; L Dogliotti; G Gorzegno; M Torta; M Tampellini; M Tucci; S Cerutti; M M Frezet; M Stivanello; G Sacchetto; A Angeli Journal: Clin Chem Date: 1999-08 Impact factor: 8.327
Authors: Robert E Coleman; Pierre Major; Allan Lipton; Janet E Brown; Ker-Ai Lee; Matthew Smith; Fred Saad; Ming Zheng; Yong Jiang Hei; John Seaman; Richard Cook Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman Journal: Bone Date: 2010-11-10 Impact factor: 4.398
Authors: Matthew R Smith; Fred Saad; Stephane Oudard; Neal Shore; Karim Fizazi; Paul Sieber; Bertrand Tombal; Ronaldo Damiao; Gavin Marx; Kurt Miller; Peter Van Veldhuizen; Juan Morote; Zhishen Ye; Roger Dansey; Carsten Goessl Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Dario C Altieri; Lucia R Languino; Jane B Lian; Janet L Stein; Irwin Leav; Andre J van Wijnen; Zhong Jiang; Gary S Stein Journal: J Cell Biochem Date: 2009-08-01 Impact factor: 4.429
Authors: J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian Journal: Oncogene Date: 2009-11-16 Impact factor: 9.867